Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
MREO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.47 - $4.72
Previous CloseN/A
Volume219.93K
Average Volume (3M)973.13K
Market Cap
$286.20M
Enterprise Value$377.77M
Total Cash (Recent Filing)$56.13M
Total Debt (Recent Filing)$601.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 18, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding159,096,880
10 Day Avg. Volume962,012
30 Day Avg. Volume973,130
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue241.50
Enterprise Value/Gross Profit1.10K
Enterprise Value/Ebitda-8.08
Forecast
1Y Price Target
$7.20Price Target Upside306.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentSetrusumab demonstrated an acceptable safety profile and the study should proceed to the final analysis.
Financial StabilityMREO ended with $56.1M cash, which the company is guiding as sufficient to fund operations into 2027.
Market OpportunitySetrusumab is expected to address a significant unmet need in osteogenesis imperfecta as an active and safe treatment, corresponding to a large market opportunity.
Bears Say
Clinical Trial UncertaintyThe Phase III Orbit study will continue towards a final analysis after missing on its second interim, which is expected to put MREO under pressure.
Price Target AdjustmentThe target price is being lowered to $5 due to increased uncertainty and adjusted potential launch timing.
Stock PerformanceMREO shares are down approximately 35% on the news.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $1.47 and its highest was $4.72 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $286.20M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 18, 2025 which is in 51 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 12, 2025. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.012 by -$0.008.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,096,880 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.012. Following the earnings report the stock price went up 9.211%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (306.78% Upside)
$7.20 (306.78% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.55%
12-Months-Change
Fundamentals
Return on Equity
-75.08%
Trailing 12-Months
Asset Growth
-34.85%
Trailing 12-Months
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
MREO Stock 12 Month Forecast
Average Price Target
$7.20
▲(306.78% Upside)
Technical Analysis
Heron Therapeutics
―
RegenXBio
―
Cartesian Therapeutics
―
Inventiva
―
Verve Therapeutics
―
Ownership Overview
1.32% Insiders
0.57% Mutual Funds
41.37% Other Institutional Investors
56.40% Public Companies and
Individual Investors